Evaluation of outcomes in patients (pts) with stage 4 non-small cell lung cancer (NSCLC 4) harboring actionable oncogenic drivers (AOD) when treated prior to report of mutation without tyrosine kinase inhibitors (TKI): An Integra Connect Database (ICD) retrospective observational study

Integra-connect-nsclc-poster

 

button_download-poster

 

Would you like to speak with a Thermo Fisher Scientific representative?
Click the button below to request contact.

request-contact-cta

 

For Research Use only. Not for use in diagnostic procedures.